Something looks to be going on with our new RC220 formulation. Have a look at the language being used and how it has changed over the past Quarter.
"Race continues ongoing development of RC220. The CMC team is actively pursuing an engineering and GMP formulation, designed for patients requiring I.V administration. This is an innovative and commercially critical program to support our cardio protection ambitions and programs still being explored like FTO & M6A."
It is very interesting they have described it as "ongoing development"
As in the March 2023 Q they described it as "developed"
"Race researchers have developed an improved & novel formulation of Zantrene
that enables peripheral intravenous (IV) delivery, expanding potential market"
Ann: Quarterly Activity Report & Appendix 4C, page-18
-
- There are more pages in this discussion • 116 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.94 |
Change
0.055(2.92%) |
Mkt cap ! $330.4M | |||
| Open | High | Low | Value | Volume |
| $1.89 | $1.96 | $1.85 | $333.0K | 174.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3105 | $1.94 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.95 | 7574 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |